Foresite Capital

Obsidian Therapeutics Announces Oversubscribed $160.5 Million Series C Financing to Drive OBX-115 Clinical Development

Retrieved on: 
Wednesday, April 3, 2024
Biotechnology, Health, Genetics, Clinical Trials, Oncology, Janus, Growth, Novo Holdings A/S, NSCLC, TIL, Patient, Wellington Management Company, Paradigm, Foresite Capital, Bristol Myers Squibb, Lung cancer, Doctor of Philosophy, Therapy, Melanoma, Investment, Atlas Venture, Pharmaceutical industry

Obsidian Therapeutics, Inc. , a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced it has closed a significantly oversubscribed $160.5 million Series C financing with a top-tier syndicate of life science investors led by new investor, Wellington Management.

Key Points: 
  • Obsidian Therapeutics, Inc. , a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced it has closed a significantly oversubscribed $160.5 million Series C financing with a top-tier syndicate of life science investors led by new investor, Wellington Management.
  • Proceeds from the financing will advance Obsidian’s lead engineered tumor-infiltrating lymphocyte (TIL) program, OBX-115, in its ongoing trials for patients with melanoma and non-small cell lung cancer (NSCLC).
  • The Company is focused on enrolling patients and reaching key clinical and regulatory milestones, as well as manufacturing scale-up ahead of pivotal trial readiness.
  • “This financing provides funding through key clinical readouts in melanoma and is the catalyst to continue expanding OBX-115 into NSCLC, where there is significant potential and high unmet need.”

Avenzo Therapeutics Announces $150 Million Oversubscribed Financing To Advance Emerging Oncology Pipeline

Retrieved on: 
Tuesday, March 26, 2024
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Private equity, CDK2, Patient, Foresite Capital, Eli Lilly and Company, New Enterprise Associates, Therapy, OrbiMed, NEA, OncoMed, Pharmaceutical industry

(“Avenzo”), a clinical-stage biotechnology company developing next generation oncology therapeutics, today announced the closing of an oversubscribed $150 million Series A-1 financing.

Key Points: 
  • (“Avenzo”), a clinical-stage biotechnology company developing next generation oncology therapeutics, today announced the closing of an oversubscribed $150 million Series A-1 financing.
  • The total capital raised since the company’s founding in August 2022 is $347 million.
  • In conjunction with the announcement, Jakob Dupont, M.D., Executive Partner, Private Equity, Sofinnova Investments, will join the Avenzo Board of Directors.
  • “The team at Avenzo has made great progress over the past 18 months since formation on our mission to advance the next generation of oncology therapies for patients,” said Athena Countouriotis, M.D., Co-founder, President and CEO of Avenzo.

Alumis Announces Upsized $259M Series C Financing to Advance Clinical-stage Pipeline of Oral Therapies Designed to Address Immune Dysfunction

Retrieved on: 
Wednesday, March 6, 2024
Foresite Capital, DSM-IV codes, Psoriasis, Uveitis, HBM, Growth, Data science, Safety, Eli Lilly and Company, Genetics, Patient, TYK2, SLE, Partnership, Vaccine

SOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Alumis Inc., a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to transform the lives of patients with immune-mediated diseases, today announced an upsized $259M Series C financing. Alumis plans to use the proceeds of the financing to initiate pivotal Phase 3 clinical trials for its lead candidate ESK-001, a highly selective and potentially best-in-class allosteric tyrosine kinase 2 (TYK2) inhibitor, in moderate to severe plaque psoriasis in the second half of 2024, as well as support the two ongoing Phase 2 clinical trials for ESK-001 in systemic lupus erythematosus (SLE), and non-infectious uveitis. The financing will also support the further advancement of Alumis’ precision data analytics and multi-platform approach to explore ESK-001’s potential application in other autoimmune indications, as well as A-005, a TYK2 inhibitor for the treatment of neuroinflammatory and neurodegenerative diseases, and its earlier-stage internal pipeline programs.

Key Points: 
  • Srinivas Akkaraju, M.D., Ph.D., Founder and Managing General Partner of Samsara BioCapital, and Richard Gaster, M.D., Ph.D., Managing Partner at venBio Partners, will join Alumis’ Board of Directors.
  • “This investment will support the continued clinical development of ESK-001, building on promising data that have demonstrated full, sustained target inhibition leading to a potentially best-in-class oral TYK2 inhibitor profile.
  • We are now starting to see how this will translate into outcomes for patients.
  • We are proud of the company’s progress and happy to continue to support and work with the Alumis team and Board of Directors in this next stage of the company’s growth.”

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Acquisition of Kinnate Biopharma Inc. by XOMA Corporation

Retrieved on: 
Friday, March 1, 2024
Foresite Capital, Acquisition, KNTE, Person, Telephone, Sale, LLP, OrbiMed

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Kinnate by XOMA Corporation (“XOMA”).

Key Points: 
  • You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Kinnate by XOMA Corporation (“XOMA”).
  • As a result of the merger, Kinnate stockholders will receive $2.3352 per share in cash and additional cash up to $0.2527 per share, plus a contingent value right.
  • To learn more about the action and your rights, go to:
    or contact Joseph E. Levi, Esq.
  • Levi & Korsinsky is a nationally recognized firm with offices in New York, Connecticut, California, and Washington, D.C.

FogPharma Announces $145 Million Financing to Support Ongoing Clinical Development of FOG-001 and Accelerate Helicon Peptide Portfolio

Retrieved on: 
Friday, March 1, 2024
Health, Other Science, General Health, Research, Science, Pharmaceutical, Biotechnology, Therapy, Foresite Capital, GV, Artificial intelligence, Colorectal cancer, Record, Cancer, Growth, Johnson & Johnson, Helicon, MBA, Symbiosis, Data science, World Health Organization, Patient, MPH, Oncology, ARCH Venture Partners, Farallon Capital, Pharmaceutical industry

Alexis Borisy, an accomplished investor and entrepreneur, also joined the company's board of directors in the position designated to Nextech.

Key Points: 
  • Alexis Borisy, an accomplished investor and entrepreneur, also joined the company's board of directors in the position designated to Nextech.
  • The financing will fund the ongoing clinical development of FOG-001, the company’s first-in-class intracellular TCF-blocking β-catenin inhibitor currently being evaluated in a Phase 1/2 study in solid tumors.
  • The round will also accelerate the development of its robust portfolio of unique discovery programs, deepen its data science capabilities and strengthen its core Helicon therapeutics platform.
  • “Millions of colorectal cancer patients have been told by their oncologists that no more can be done for them.

Odyssey Therapeutics Announces $101 Million Series C Financing

Retrieved on: 
Tuesday, December 5, 2023
FDA, Other Health, Finance, Pharmaceutical, Business, Oncology, General Health, Professional Services, Infectious Diseases, Genetics, Clinical Trials, Biotechnology, Science, Other Science, Research, Health, Foresite Capital, Therapy, Ideation, Patient, Investment, Goldman Sachs, Messenger, SVB Securities, OrbiMed, Drug discovery, HBM, Drug development, Pharmaceutical industry, Boston, Odyssey

This Series C financing brings the total capital raised since founding in late 2021 to $487 million.

Key Points: 
  • This Series C financing brings the total capital raised since founding in late 2021 to $487 million.
  • Proceeds will support the advancement of multiple programs into clinical studies and the continuation of investment in discovery to build a sustainable model for therapeutic innovation.
  • This unique set of tools enables Odyssey to identify drug targets with the highest clinical potential in a modality-agnostic fashion.
  • “Odyssey continues to accelerate multiple pre-clinical programs in immunology and oncology,” said Jeff Leiden, M.D., Ph.D., Chairman of the Odyssey board.

Foresite Cybersecurity Partners with Crowdstrike

Retrieved on: 
Tuesday, December 5, 2023
Foresite Capital, Investment, CrowdStrike, Organization, Small business, Partnership, Market, Video game

OVERLAND PARK, Kan., Dec. 5, 2023 /PRNewswire/ -- Foresite, announces a new partnership with CrowdStrike, a global leader in cloud-delivered protection of endpoints, cloud workloads, identity, and data protection. This collaboration will provide customers the opportunity to leverage the industry-leading, AI-Powered CrowdStrike Falcon® platform with Foresite's proprietary ProVision Managed Services for Foresite's Channel Partners and their customers.

Key Points: 
  • OVERLAND PARK, Kan., Dec. 5, 2023 /PRNewswire/ -- Foresite, announces a new partnership with CrowdStrike , a global leader in cloud-delivered protection of endpoints, cloud workloads, identity, and data protection.
  • This collaboration will provide customers the opportunity to leverage the industry-leading, AI-Powered CrowdStrike Falcon ® platform with Foresite's proprietary ProVision Managed Services for Foresite's Channel Partners and their customers.
  • With the addition of the Crowdstrike Falcon platform, we have the industry's recognized leader to protect businesses.
  • Foresite delivers a broad suite of cybersecurity and compliance solutions through hundreds of resellers to help clients meet compliance requirements and stay protected against evolving cyber threats.

Foresite Capital Strengthens Investor Relations and Business Development Teams with Addition of Hadi Tabbaa as Managing Director

Retrieved on: 
Thursday, September 28, 2023
Professional Services, Health, Other Health, Finance, Asset Management, Biotechnology, Marketing, Economics, Foresite Capital, Black Rock, Abir Al-Tabbaa, JD, Coatue Management, Stanford Law School, Multimedia, Lehman Brothers, Rice University, McKinsey & Company, Capital, Security (finance)

Foresite Capital , a multi-stage healthcare and life sciences investment firm, announces today the appointment of Hadi Tabbaa as managing director of investor relations and business development.

Key Points: 
  • Foresite Capital , a multi-stage healthcare and life sciences investment firm, announces today the appointment of Hadi Tabbaa as managing director of investor relations and business development.
  • With more than two decades of experience in investor relations, capital formation and corporate business development, Hadi will oversee these efforts at Foresite, working closely with Foresite Capital CEO Jim Tananbaum and the current investor relations team to deepen the company's relationships with existing and prospective investors.
  • View the full release here: https://www.businesswire.com/news/home/20230928666132/en/
    Tabbaa joins Foresite Capital from B Capital , where he was a partner and global head of investor relations.
  • I look forward to strengthening our investor partnerships and building a world-class investor relations and business development function here,” Mr. Tabbaa added.

Foresite Cybersecurity adds Horizon3.ai’s NodeZero™ to their ProVision Platform for Continuous Security Posture Verification

Retrieved on: 
Wednesday, September 6, 2023
Data Management, Security, Technology, Software, Networks, Artificial Intelligence, Internet, Security operations center, Provision, 1-Click, Organization, Partnership, Risk management, Foresite Capital

This new offering will further enable Foresite customers to simplify risk reduction, improve security operations, streamline security compliance, prioritize security tasks, and reduce the complexity of cybersecurity overall.

Key Points: 
  • This new offering will further enable Foresite customers to simplify risk reduction, improve security operations, streamline security compliance, prioritize security tasks, and reduce the complexity of cybersecurity overall.
  • “We are excited to partner with Horizon3.ai to bring NodeZero’s powerful autonomous testing capability into our ProVision platform to better serve our customers,” says Marc Brungardt, Foresite’s President.
  • The NodeZero platform empowers organizations to reduce their security risk and continuously improve their security posture.
  • “Today, cybersecurity risk assessments, powered by autonomous penetration testing, are becoming a continuous and valuable service, instead of being seen as a once-per-year pentesting effort.”

Pardes Biosciences Announces Closing of Tender Offer

Retrieved on: 
Thursday, August 31, 2023
Intellectual property, SVB Securities, CVR, Sub, COVID-19, Foresite Capital, Expiration date, Mergers and acquisitions, PRDS, Expiration, Cryptocurrency, Pardes

The tender offer and related withdrawal rights expired at one minute after 11:59 p.m. Eastern Time on August 30, 2023 (the Expiration Date).

Key Points: 
  • The tender offer and related withdrawal rights expired at one minute after 11:59 p.m. Eastern Time on August 30, 2023 (the Expiration Date).
  • As of the Expiration Date, a total of 37,836,066 shares of Pardes common stock were validly tendered, and not validly withdrawn, representing approximately 60.9% of the outstanding shares of Pardes common stock as of the Expiration Date.
  • As of the Expiration Date, the number of shares validly tendered in accordance with the terms of the tender offer and not validly withdrawn satisfied the minimum tender condition, and all other conditions to the offer were satisfied or waived.
  • Following the closing of the tender offer, Merger Sub merged with and into Pardes and all shares of Pardes common stock that had not been validly tendered were converted into the right to receive the Offer Price (the Merger).